ESMO 2020 | REACTION clinical trial update

Benjamin Besse, MD, PhD, Institut Gustave Roussy, Villejuif, France discusses REACTION (NCT02580994), a randomized, Phase II study of etoposide and cis/carboplatin with or without pembrolizumab in untreated extensive small cell lung cancer. The combination of pembrolizumab with platinum-etoposide was well-tolerated but did not improve progression-free survival over platinum-etoposide alone. The overall survival (OS) showed the combination significantly improved OS at the 1-sided, 10% level. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).